Gut Priming With Oral Bovine Colostrum for Preterm Neonates; Randomized Control Trial
NCT ID: NCT03926390
Last Updated: 2020-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2018-09-15
2019-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feeding Bovine Colostrum to Preterm Infants
NCT02054091
Oral Care With Colostrum for Preventing Late-onset Sepsis in Preterm Infants
NCT06534632
Bovine Colostrum in Prevention of Necrotizing Enterocolitis and Sepsis in Very Low Birth Weight Neonates
NCT04886674
Bovine Colostrum for Preterm Newborns
NCT03085277
Bovine Colostrum as a Human Milk Fortifier for Preterm Infants
NCT03822104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The enrolled patients was subdivided into two groups; group A are infants with non bovine colstrum and group B with bovine colostrum All infants received the standard neonatal care and underwent follow-up from birth until reach 37 week corrected gestational age, discharge or death whichever came first.
I. Data Collection: Careful history taking
1. Antenatal history including: rupture of membrane, Chorioamnionitis, history of urinary tract infection.
2. Natal history including: mode of delivery, place of delivery, the need for resuscitation, recorded Apgar score at 1minute and 5 minutes.
3. Postnatal history including: age of admission in neonatal intensive care unit, symptoms suggest infection.
II. Thorough clinical assessment:
1. Weight and Occiptofrontal circumference (twice weekly).
2. Complete examination including cardiovascular, respiratory, abdominal and neurological examination.
III. Laboratory investigations:
1. Complete blood picture, C-reactive protein on admission and repeated twice weekly
2. Blood culture before starting treatment and with any suspected sepsis.
3. In first 24 hours and the end of second week : Collecting peripheral blood mononuclear cells to be analyzed for cellular parameters by flow cytometry (CD4 T cells, CD25 L, FOXP3). Three subsets of CD4+ T cells will be defined according to CD25 staining: CD25- , CD25 low, and CD25 high. Cells expressing CD25 high will be chosen and gated for the detection of FOXP3+ T cells.
IV. Radiological investigations:
Chest X-ray (It was done on admission and repeated when needed). Abdominal X-ray (when necrotizing enterocolitis is suspected). Abdominal ultrasound (when necrotizing enterocolitis is suspected).
V. Follow-up and end-point of the study:
All infant underwent follow-up from birth until reach 37 week corrected gestational age, discharge or death whichever came first.NPO for more than 24 hours
The following primary outcome data was recorded:
* Clinical examination and laboratory investigations when clinically indicated for evidence of sepsis.
* Clinical examination and radiological investigations when clinically indicated for evidence of NEC.
A secondary outcome measure includes weight increment per kg per week, duration of hospitalization, mortality if any, monitoring adverse effects of treatment (if any); such as emesis, increased gastric residuals, increased abdominal girth, diarrhea, skin rash. Long term outcome includes necrotizing enterocolitis, and intracranial hemorrhage.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non bovine colostrun
Preterm received preterm formula
No interventions assigned to this group
Bovine colostrum group
Preterm received bovine colostrum as trophic feeding
Bovine colostrum
bovine colostrum for first 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bovine colostrum
bovine colostrum for first 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Proved early onset sepsis.
* Life-threatening congenital abnormalities.
* Inborn error of metabolism.
* Chromosomal aberrations.
* Neonates with underlying gastrointestinal problems (such as GIT anomalies) that prevent enteral feeding.
* Perinatal asphyxia.
24 Hours
28 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rania Ismail
Clinical professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hisham Awad
Role: PRINCIPAL_INVESTIGATOR
professor of pediatrics Ain Shams university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medicin
Giza, Abasseya, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU 50 / 2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.